Company News

Latest News

Polaris Group Completes Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with FDA to Treat Malignant Pleural Mesothelioma
2025/6/9-Polaris Group (The Company, TWSE:6550) previously adopted a rolling submission approach for...
Read more »
Polaris Group commenced the ground-breaking ceremony for Zhunan plant today with Chairman & CEO Dr. Hsu sharing the 5-year dual-engine accelerated growth strategy
2025/4/15-On April 15th, 2025, Polaris Group-KY (6550) held a groundbreaking ceremony for the new plant...
Read more »
Polaris Group-KY (6550) Announces Subsidiary PPI Signed Exclusive Distribution Agreement with Er-Kim Pharmaceuticals to Commercialize Pegargiminase (ADZODI) for Malignant Pleural Mesothelioma (MPM) in Multiple EMEA Markets
2025/4/14-Polaris Group-KY (6550) announces today its US California subsidiary Polaris Pharmaceuticals...
Read more »
Polaris Group-KY (6550) Announces Subsidiary PPI Signed Exclusive Partnership with Tabuk Pharmaceuticals to introduce ADI-PEG20 (ADZODI), an innovative First-in-Class arginine degradation innovative drug for hard-to-treat cancers in the Kingdom of Saudi Arabia and GCC Region
2025/4/14-Polaris Group-KY (6550) announces today its US California subsidiary Polaris Pharmaceuticals...
Read more »
Polaris Group-KY Successfully Completes 2024 Capital Injection to Accelerate Dual-Engine Core Strategy and Enhance Future Growth Momentum
2024/12/10-Polaris Group-KY announced that it has successfully completed its Year 2024 capital injection...
Read more »
The Polaris Pharmaceutical's new drug for mesothelioma has increased the three-year survival rate by fourfold, as published in the internationally renowned medical journal JAMA Oncology.
2024/2/15-The breakthrough clinical trial of a rare and aggressive cancer treatment reveals: Polaris...
Read more »
1 2 3 4 … 6
Scroll to Top
This site is registered on wpml.org as a development site.